Marinus Pharmaceuticals, Inc. Banner Image

Marinus Pharmaceuticals, Inc. has reached its limit for free report views

Work for Marinus Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Marinus Pharmaceuticals, Inc.

  • Ticker MRNS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Marinus Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Radnor, Pennsylvania
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formsMore intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company is planning to initiate a Phase 3 trial in status epilepticus.
4.8 / 5.0 (222)

Marinus Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 222 reviews.

Marinus Pharmaceuticals, Inc.

Most Recent Annual Report

Marinus Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Marinus Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Marinus Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!